2015
DOI: 10.1051/medsci/20153110010
|View full text |Cite
|
Sign up to set email alerts
|

Aspects moléculaires des lymphomes T périphériques (1)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 97 publications
(151 reference statements)
0
1
0
Order By: Relevance
“…With the aim to gain further insight into the pathogenesis and the biological behavior of rare cutaneous lymphomas, such as CD8+ cytotoxic lymphomas, much can be learned and transferred from recent work on molecular profiling of systemic PTCL-NOS, including gene expression and deep sequencing analysis [ 19 , 21 , 22 ]. Gene expression profiling has once again confirmed that within the generic term of systemic PTCL-NOS, there is extensive molecular heterogeneity as already evidenced by divergent clinical, histological and immunophenotypical data [ 18 , 23 , 24 ]. Moreover, taking the limited therapeutic opportunities and the often dismal prognosis of PTCL-NOS into consideration, the progress in deciphering the mutational landscape and the subtype-specific gene expression profiles has revealed several novel therapeutic options [ 25 ].…”
Section: Discussionmentioning
confidence: 76%
“…With the aim to gain further insight into the pathogenesis and the biological behavior of rare cutaneous lymphomas, such as CD8+ cytotoxic lymphomas, much can be learned and transferred from recent work on molecular profiling of systemic PTCL-NOS, including gene expression and deep sequencing analysis [ 19 , 21 , 22 ]. Gene expression profiling has once again confirmed that within the generic term of systemic PTCL-NOS, there is extensive molecular heterogeneity as already evidenced by divergent clinical, histological and immunophenotypical data [ 18 , 23 , 24 ]. Moreover, taking the limited therapeutic opportunities and the often dismal prognosis of PTCL-NOS into consideration, the progress in deciphering the mutational landscape and the subtype-specific gene expression profiles has revealed several novel therapeutic options [ 25 ].…”
Section: Discussionmentioning
confidence: 76%